TuHURA Biosciences (HURA) Common Equity (2010 - 2026)

TuHURA Biosciences' Common Equity history runs 17 years deep, the most recent figure standing at $23.2 million for Q1 2026.

• On a quarterly basis, Common Equity rose 135.28% year-over-year to $23.2 million in Q1 2026; TTM through Mar 2026 was $23.2 million, a 135.28% increase from a year earlier, with the FY2025 full-year figure at $20.9 million, up 7415.29% from the prior year.
• Common Equity improved to $23.2 million in Q1 2026 per HURA's latest filing, from $20.9 million in the prior quarter.
• Across five years, Common Equity topped out at $23.2 million in Q1 2026 and bottomed at -$7.0 million in Q2 2024.
• The 5-year median for Common Equity is $9.4 million (2022), against an average of $7.0 million.
• Across the five-year window, Common Equity sank 1051.96% in 2024 and soared 7415.29% in 2025, its largest moves.
• Year by year, Common Equity stood at $12.3 million in 2022, then plunged by 112.67% to -$1.6 million in 2023, then soared by 117.87% to $278530.0 in 2024, then surged by 7415.29% to $20.9 million in 2025, then grew by 10.79% to $23.2 million in 2026.
• Per Business Quant, the three latest HURA Common Equity figures stand at $23.2 million (Q1 2026), $20.9 million (Q4 2025), and $16.8 million (Q3 2025).